BMC pregnancy and childbirth · 2026
Maternal and fetal outcomes in patients with congenital heart disease associated with pulmonary arterial hypertension in high-altitude areas: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lu Xiang-Ting, Chen Xue-Rong, Jin Qing, Xu Yun-Yan, Jin Pei-Yun, Lu Yi-Bing, Dai Hai-Long
Аннотация
OBJECTIVES: Pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH) increases maternal and fetal risk. This study aimed to analyze maternal and fetal outcomes in patients with CHD-PAH in high-altitude areas.
METHODS: The pregnant women with CHD were analyzed retrospectively from 2012 to 2022. Pulmonary artery systolic pressure (PASP) was estimated by echocardiography. Patients were categorized into four groups: no PAH (PASP < 40 mmHg), mild (40 mmHg≤PASP < 50 mmHg), moderate (50 mmHg≤PASP < 70 mmHg) and severe PAH (PASP ≥ 70 mmHg).
RESULTS: 429 pregnant women were included in this study, 187 with no PAH, 102 with mild PAH, 79 with moderate PAH, 61 with severe PAH. The severe PAH group had the highest proportions of NYHA functional classes III/IV, SpO2<90%, and elevated NT-proBNP levels, but a lower rate of regular prenatal checkups compared with the no PAH and mild PAH groups (P < 0.05). The severe PAH group showed significantly higher rates of low birth weight, preterm birth, and neonatal asphyxia (P < 0.001). Independent risk factors for maternal and infant complications included NYHA functional classes III-IV (OR = 6.342, 95% CI: 2.28-17.894), NT-proBNP ≥ 250 ng/L (OR = 3.148, 95% CI: 1.121-8.840), moderate PAH (OR = 6.263, 95% CI: 1.657-23.669), and severe PAH (OR = 7.125, 95% CI: 1.792-28.334), whereas higher BMI was a protective factor (OR = 0.802, 95% CI: 0.712-0.904).
CONCLUSIONS: The level of PASP, NT-proBNP, and NYHA function class, BMI may be useful in risk stratification in pregnancy with CHD-PAH in high-altitude areas.
METHODS: The pregnant women with CHD were analyzed retrospectively from 2012 to 2022. Pulmonary artery systolic pressure (PASP) was estimated by echocardiography. Patients were categorized into four groups: no PAH (PASP < 40 mmHg), mild (40 mmHg≤PASP < 50 mmHg), moderate (50 mmHg≤PASP < 70 mmHg) and severe PAH (PASP ≥ 70 mmHg).
RESULTS: 429 pregnant women were included in this study, 187 with no PAH, 102 with mild PAH, 79 with moderate PAH, 61 with severe PAH. The severe PAH group had the highest proportions of NYHA functional classes III/IV, SpO2<90%, and elevated NT-proBNP levels, but a lower rate of regular prenatal checkups compared with the no PAH and mild PAH groups (P < 0.05). The severe PAH group showed significantly higher rates of low birth weight, preterm birth, and neonatal asphyxia (P < 0.001). Independent risk factors for maternal and infant complications included NYHA functional classes III-IV (OR = 6.342, 95% CI: 2.28-17.894), NT-proBNP ≥ 250 ng/L (OR = 3.148, 95% CI: 1.121-8.840), moderate PAH (OR = 6.263, 95% CI: 1.657-23.669), and severe PAH (OR = 7.125, 95% CI: 1.792-28.334), whereas higher BMI was a protective factor (OR = 0.802, 95% CI: 0.712-0.904).
CONCLUSIONS: The level of PASP, NT-proBNP, and NYHA function class, BMI may be useful in risk stratification in pregnancy with CHD-PAH in high-altitude areas.